Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pliability × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 211 Magnetic Resonance Spectroscopy 186 Radiotherapy 183 Radiosurgery 162 Gemcitabine 137 Nivolumab 132 pembrolizumab 129 enzalutamide 122 Prednisone 120 Cisplatin 110 Leuprolide 108 Androgen Antagonists 107 Abiraterone Acetate 99 Sunitinib 94 Specimen Handling 87 Goserelin 81 bicalutamide 78 Carboplatin 78 Surveys and Questionnaires 75 Ipilimumab 73 gallium 68 PSMA-11 71 Blood Specimen Collection 69 apalutamide 68 Radiation 66 Biopsy 65 Everolimus 64 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 62 Standard of Care 61 Paclitaxel 60 cabozantinib 57

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04485767 2024-08-20

RESIST-ADT (Androgen Deprivation Therapy)

Dana-Farber Cancer Institute

Phase NA Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡